

Quarterly update regarding the Authorized Adjustment

The Alberta government, the Alberta Pharmacists' Association and Alberta Blue Cross continue working collaboratively to monitor pharmacy compensation expenditures and trends for drug benefit fees and pharmacy services. As previously communicated in Benefact 865, a provision exists to enable an Authorized Adjustment mechanism, through a consultative process, should expenditures trend towards exceeding established budget targets.

With the completion of the third fiscal quarter (October 1 to December 31, 2022), expenditures remain within budget targets and, as a result, there was no need to initiate consultations on the Authorized Adjustment.

Temporary Benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Humatrope 6 mg Injection (DIN 02243077) and Humatrope 12 mg Injection (DIN 02243078) manufactured by Eli Lilly Canada Inc., **Humatrope 24 mg Injection (DIN 02243079)** manufactured by Eli Lilly Canada Inc. will be considered a temporary benefit for the ADBL. This grouping was added to the Critical Supply Product List **January 26, 2023**.

As of **January 26, 2023**, all claims for Humatrope 24 mg Injection (DIN 02243079) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Removal of Temporary Benefits from the *ADBL*

Due to the shortages of Glycopyrrolate 0.2 mg/1 ml (0.2 mg/ml) Injection USP (DIN 02473879) manufactured by Sterimax Inc., Glycopyrrolate 0.4 mg/2 ml (0.2 mg/ml) Injection USP (DIN 02473895) manufactured by Sterimax Inc., Glycopyrrolate 4 mg/20 ml (0.2 mg/ml) Injection USP (DIN 02473887) manufactured by Sterimax Inc., and Glycopyrrolate 0.2 mg/ml Injection (DIN 02039508) manufactured by Sandoz Canada Inc., Glycopyrrolate 0.2 mg/ml Injection (DIN 02382857) manufactured by Omega Laboratories Limited was added as a temporary benefit for the *ADBL*.

Sterimax Inc. and Sandoz Canada Inc. have advised Alberta Blue Cross that the shortages for Glycopyrrolate 0.2 mg/1 ml (0.2 mg/ml) Injection USP (DIN 02473879), Glycopyrrolate 0.4 mg/2 ml (0.2 mg/ml) Injection USP (DIN 02473895), and Glycopyrrolate 0.2 mg/ml Injection (DIN 02039508) have been resolved.

Glycopyrrolate 0.2 mg/ml Injection (DIN 02382857) will no longer be considered a temporary benefit for the *ADBL* after **February 27, 2023**. The above grouping was removed from the Critical Supply Product List **January 25, 2023**.

Due to the shortage of Maxidex 0.1% Ophthalmic Suspension (DIN 00042560) manufactured by Novartis Pharmaceuticals Canada Inc., Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865) manufactured by Pharma Stulln Inc. was added as a temporary benefit for the *ADBL*.

Novartis Pharmaceuticals Canada Inc. have advised Alberta Blue Cross that the shortage for Maxidex 0.1% Ophthalmic Suspension (DIN 00042560) have been resolved.

continued next page

PHARMACY BENEFACT

continued from previous page

Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865) will no longer be considered a temporary benefit for the **ADBL after March 2, 2023**. The above grouping was removed from the Critical Supply Product List **January 31, 2023**.

Due to the shortage of Vyvanse 30 mg Capsule (DIN 02322951) manufactured by Takeda Canada Inc., Vyvanse 10 mg Capsule (DIN 02439603) manufactured by Takeda Canada Inc. was added as a temporary benefit for the **ADBL**.

Takeda Canada Inc. has advised Alberta Blue Cross that the shortage for Vyvanse 30 mg Capsule (DIN 02322951) have been resolved.

Vyvanse 10 mg Capsule (DIN 02439603) will no longer be considered a temporary benefit for the **ADBL after February 7, 2023**. The above grouping was removed from the Critical Supply Product List **February 7, 2023**.

Product supply shortage addressed for the **ADBL**

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage for Act Dextroamphetamine SR 15 mg Sustained-Release Capsule (DIN 02448327), has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 1, 2023**. The following grouping was removed from the Critical Supply Product List **January 30, 2022**.

DEXTROAMPHETAMINE SULFATE

15 MG SUSTAINED-RELEASE CAPSULE

00002448327	ACT DEXTROAMPHETAMINE SR	APH	\$ 0.9898
00001924567	DEXEDRINE	PAL	\$ 1.1637

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

